MRTX - Mirati Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
29.60
+0.60 (+2.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close29.00
Open29.05
Bid26.80 x 100
Ask28.45 x 300
Day's range28.50 - 29.95
52-week range2.70 - 30.50
Volume345,520
Avg. volume437,804
Market cap826.334M
Beta2.39
PE ratio (TTM)N/A
EPS (TTM)-3.07
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.43
Trade prices are not sourced from all markets
  • Forbeslast month

    Nektar Notches New Highs As Stock Triples In Two Months

    Biotech and pharma stocks dominate our list of top charts to watch today.

  • MarketWatchlast month

    Harry Boxer’s three health-care stocks to watch today

    In focus: Collegium Pharmaceutical, Mirati Therapeutics and Nektar Therapeutics.

  • Globe Newswirelast month

    BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region

    BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world. Sitravatinib is an investigational tyrosine kinase inhibitor that has demonstrated potent inhibition of receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, MER), split family receptors (VEGFR2, KIT) and RET.

  • Associated Press4 months ago

    Mirati reports 3Q loss

    The San Diego-based company said it had a loss of 65 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • Forbes4 months ago

    Four Biotech And Health Care Breakouts

    Four biotech and health-related stocks top our list of momentum charts to watch.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes